The Feldene Experience: A Case Study

  • R. M. Sachs
  • G. S. Dieck
Part of the Health Systems Research book series (HEALTH)

Abstract

The following illustrates an actual experience involving allegations of safety problems with the nonsteroidal anti-inflammatory drug (NSAID) Feldene (piroxicam). It is intended to serve as a case study of the ramifications of examining complex issues of risk analysis in a public forum under volatile conditions. Although the safety of the drug was ultimately established, both the process and its conclusion had significant impact on the manufacturer, the regulatory agency, physicians and patients. This discussion will focus particularly on the roles played in this episode by pharmacoepidemiology and the media.

Keywords

Toxicity Arthritis Aspirin Marketing Perforation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Food and Drug Administration. Center for Drugs and Biologies (1984) Minutes of the Arthritis Advisory Committee meeting, Bethesda, Maryland, October 25–26Google Scholar
  2. 2.
    Food and Drug Administration. Center for Drugs and Biologies (1985) Minutes of the Arthritis Advisory Committee meeting, Bethesda, Maryland, April 29–30Google Scholar
  3. 3.
    Ferriman A (1985) “Arthritis Drug Alert After 77 Patients Die”, The Observer, December 22Google Scholar
  4. 4.
    Letter to Secretary Bowen of the Department of Health and Human Services (1986) from Sidney Wolfe, Director, Health Research Group, January 8.Google Scholar
  5. 5.
    Transcript of Proceedings, United States of America before the Food and Drug Administration, In the Matter of: Piroxicam (1986) Docket Number 86P-0023, Bethesda, Maryland, February 28Google Scholar
  6. 6.
    Letter to Sidney M. Wolfe, Director, Health Research Group (1986) from Secretary Bowen of the Department of Health and Human Services, July 7Google Scholar
  7. 7.
    Pfizer Inc. (1986) Submission on the Petition of Public Citizen Health Research Group regarding Feldene (piroxicam), Food and Drug Administration, Docket Number 86P-0023, March 17Google Scholar
  8. 8.
    Food and Drug Administration, Center for Drugs and Biologies (1986) Recommendation in Piroxicam Imminent Hazard Proceeding, May 14Google Scholar
  9. 9.
    Memorandum to Secretary of Health and Human Services Otis Bowen (1986) from Frank E. Young, Commissioner, Food and Drug Administration, May 27Google Scholar
  10. 10.
    Sachs RM, Bortnichak EA (1986) An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 81 (suppl 5B): 49–55PubMedGoogle Scholar
  11. 11.
    Weber JCP (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo EP (eds) Advances in Inflammation Research Vol. 6. New York: Raven Press, pages 1–7Google Scholar
  12. 12.
    FDA (1986) personal communicationGoogle Scholar
  13. 13.
    Meisel AD (1986) Clinical benefits and comparative safety of piroxicam: analysis of worldwide clinical trials data. Am J Med 81 (suppl 5B): 15–21PubMedGoogle Scholar
  14. 14.
    Bortnichak EA, Sachs RM (1986) Piroxicam in recent epidemiologic studies. Am J Med 81 (suppl 5B)44–48PubMedGoogle Scholar
  15. 15.
    Stipp D (1988) “Scientists use medical-record data bases to detect adverse side-effects of drugs”, The Wall Street Journal, March 24, p 33Google Scholar
  16. 16.
    Beard K, Walker AM, Perera DR, Jick H (1987) Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 147: 1621–1623PubMedCrossRefGoogle Scholar
  17. 17.
    Carson JL, Strom BL, Soper KA et al. (1987) The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 147: 85–88PubMedCrossRefGoogle Scholar
  18. 18.
    Ray WA (1986) Tennessee Medicaid Database Study at Vanderbilt University. Correspondence (February 25 )Google Scholar
  19. 19.
    Rawson NSB, Inman WHW (1986) Prescription-event monitoring: recent experience with 5 NSAIDs. Med Tox 1 (suppl 1): 79–82Google Scholar
  20. 20.
    Levy M, Miller DR, Kaufman DW, et al. (1988) Major upper gastrointestinal tract bleeding: relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med 148: 281–285PubMedCrossRefGoogle Scholar
  21. 21.
    Sommerville KW, Falkner G, Langman M (1986) Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet I: 462–464CrossRefGoogle Scholar
  22. 22.
    Haglund U, Frost L, Wiholm BE: An evaluation of anti-inflammatory and analgesic drug intake among patients with acute gastrointestinal bleeding (abstr)Google Scholar
  23. 23.
    Giereksky KE, Revhaug A, Warloe T, et al. (1986) Can the incidence of gastrointestinal hemorrhage caused by drugs be reduced? Tidsskr Nor Laegeforen 106: 662–666Google Scholar
  24. 24.
    O’Brien JD, Burnham WR (1985) Bleeding from peptic ulcers and use of non-steroidal antiinflammatory drugs in the Romford area. Br Med J 291: 1609–1610CrossRefGoogle Scholar
  25. 25.
    The Pink Sheet (1987) In Brief: “The FDA’s imbroglio”, March 2Google Scholar
  26. 26.
    Data on file, Pfizer, Inc., New YorkGoogle Scholar
  27. 27.
    Sachs RM, Dieck GS (1987) Industry perspectives and the contributions of pharmacoepidemiology to public health. In: Edlavitch S (ed) Pharmacoepidemiology, Proceedings of the Third International Conference on Pharmacoepidemiology, Minneapolis (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • R. M. Sachs
  • G. S. Dieck

There are no affiliations available

Personalised recommendations